GlassScriptPhysician profile
Alfonso E Reyes
NPI 1225112659
$1,858.87
in general payments reported to CMS, 2019-2025
21 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.74 · 2020: $160 · 2021: $171 · 2022: $229 · 2023: $109 · 2024: $284 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $473.68 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $266.90 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.91 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $175.01 | 2020-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $88.37 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.19 | 2024-2025 | |
| Amgen INC. | $78.83 | 2020-2023 | Otezla, Repatha, Evenity |
| Optinose US, INC. | $76.43 | 2019-2025 | |
| Exact Sciences Corporation | $62.47 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.72 | 2021-2023 | Trulance, Xifaxan |
| Astellas Pharma US INC | $45.90 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $42.48 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Hologic Sales and Service, LLC | $29.66 | 2025 | Sentimag |
| Abbott Laboratories | $22.50 | 2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $21.68 | 2025 | Edarbi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.41 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $18.71 | 2025 | Inspire |
| Pfizer INC. | $18.11 | 2022 | |
| Shire North American Group INC | $18.01 | 2019 | |
| Merck Sharp & Dohme LLC | $15.34 | 2021 | |
| Edwards Lifesciences Corporation | $13.56 | 2024 | Sapien 3 Ultra Resilia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.